Drug Details
| General Information of the Drug (ID: DR8350) | ||||
|---|---|---|---|---|
| Name |
Cyclosporin
|
|||
| Synonyms |
cyclosporin A; cyclosporine; Ciclosporin; 59865-13-3; Cyclosporine A; Sandimmune; Sandimmun; Neoral; Cyclosporin; Ciclosporine; Gengraf; Ramihyphin A; Sandimmun Neoral; Sang-35; Ciclosporina; Ciclosporinum; Consupren; Equoral; Neoplanta; UNII-83HN0GTJ6D; Antibiotic S 7481F1; SangCyA; MFCD00274558; 83HN0GTJ6D; MLS001333756; CHEBI:4031; CSA; S-Neoral; Cipol N; Sigmasporin Microoral; Cyclosporin A solution; DSSTox_CID_365; Ciclosporin (Ciclosporin A); DSSTox_RID_75541; DSSTox_GSID_20365; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; SDZ-OXL 400; Ciclosporin A; OL 27-400; Abrammune; Imusporin; Optimmune; Seciera; Vekacia; Papilock Mini; Arpimune ME; Zinograf ME; Sandimmune Neoral; Ciclosporina Germed; (R-(R*,R*-(E)))-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); CYA; SMR000058578; Cicloral (antibiotic); Debio088; Sang 35; Cyclosporine [USAN:USP]; Ciclosporine [INN-French]; Ciclosporinum [INN-Latin]; Ciclosporina [INN-Spanish]; Cyclospori; Sigmasporin; Cyclokat; Mitogard; Papilock; Pulminiq; Zyclorin; CicloMulsion; Ciclosporin;; CCRIS 1590; Ciclosporin DT; Consupren S; NSC290193; Modusik-A; HSDB 6881; NeuroSTAT; 1cyn; 2wfj; 4jjm; NSC-290193; Cipol-N; NCGC00016890-01; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,2; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19; (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl); Cyclo(((E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl); Cyclo[[(E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]; DRG-0275; Prestwick_731; Ciclosporin [INN]; CAS-59865-13-3; NSC 290193; CsA & IFN.alpha.; 1c5f; 2z6w; S 7481F1; Cyclosporine manufacturer; Prestwick2_000435; Prestwick3_000435; CHEMBL160; Sang-2000; SCHEMBL3491; SCHEMBL4442; Nova-22007; Ikervis (opthalmic solution); BSPBio_000450; Cyclosporin A & IFN.alpha.; MLS000028376; MLS002153454; MLS002207033; Verkazia (opthalmic solution); SDZ-OXL-400; BPBio1_000496; GTPL1024; ANTIBIOTIC S-7481F1; DTXSID0020365; CHEBI:92233; AOB2581; ATH-002; OLO-400; CB-01-09 MMX; HMS1569G12; HMS2089A09; HMS2096G12; HMS2230M14; HMS3713G12; 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine]; 30-Ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); Cyclosporin A, Ready Made Solution; EX-A4110; HY-B0579; Tox21_110667; Tox21_301849; BDBM50022815; DE-076; ST-603; Cyclosporin A, >=98.5% (TLC); AKOS015969287; Tox21_110667_1; CCG-208184; DB00091; EBD2126862; KS-1257; SDCCGSBI-0050230.P004; NCGC00093704-12; NCGC00164258-01; NCGC00164258-02; NCGC00164258-03; NCGC00255232-01; AT-12519; C042; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl); OL-27400; SBI-0050230.P003; AB0090560; OL-27-400; 5946-EP0930075A1; 5946-EP2289877A1; 5946-EP2292601A1; 5946-EP2292602A1; 5946-EP2292603A1; 5946-EP2292604A2; 5946-EP2292618A1; 5946-EP2293650A1; 5946-EP2298737A1; 5946-EP2298739A1; 5946-EP2298740A1; 5946-EP2298741A1; 5946-EP2298771A2; 5946-EP2301920A1; 5946-EP2301940A1; 5946-EP2308843A1; 5946-EP2308861A1; J10181; J90049; 865C133; Cyclosporin A, VETRANAL(TM), analytical standard; Q367700; SR-01000780563; Q-200913; SR-01000780563-3; BRD-K03222093-001-01-8; BRD-K13533483-001-03-0; Ciclosporin, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, >=95% (HPLC), solid; Cyclosporine, United States Pharmacopeia (USP) Reference Standard; Ciclosporin for system suitability, European Pharmacopoeia (EP) Reference Standard; Cyclosporin A, from Tolypocladium inflatum, BioReagent, for molecular biology, >=95%; Cyclosporine, Pharmaceutical Secondary Standard; Certified Reference Material; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-((1R,2R,E)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17; 104250-72-8; 30-Ethyl-33-((E)-1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Plaque psoriasis [ICD-11: EA90] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C62H111N11O12
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
|
|||
| InChI |
1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
|
|||
| InChIKey |
PMATZTZNYRCHOR-CGLBZJNRSA-N
|
|||
| CAS Number |
CAS 59865-13-3
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Acarbose | Actinoplanes utahensis | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IL17 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | IL22 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IL23 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male BALB/c mice aged 6 weeks were used in this study. | |||||
| Experimental
Result(s) |
Acar and low-dose CsA in combination alleviates psoriatic skin lesions by inhibiting inflammation. | |||||
| Mycophenolate mofetil | Penicillium stoloniferum | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Clinical Trial | |||||
| Experimental
Result(s) |
The introduction of MMF combined with the reduction of at least 50% of CNI dose allowed the renal function of liver transplant recipients to significantly improve at 1 year, without any rejection episode and without significant secondary effects. | |||||
| Mycophenolate mofetil + Corticosteroid | Click to Show/Hide the Molecular Data of This NP | |||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Clinical trial | |||||
| Experimental
Result(s) |
Triple immunosuppressive therapy significantly reduced proteinuria and preserved renal function in refractory NS patients. | |||||
| β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Schisandrol B | Schisandra chinensis | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | LDHA | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Increase | ATP generation | ||||
| Induction | ROS generation | |||||
| In-vitro Model | HK2 | CVCL_0302 | Healthy | Homo sapiens | ||
| Experimental
Result(s) |
Sch B appears to protect against CsA-induced nephrotoxicity by decreasing oxidative stress and cell death. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Calcineurin (PPP3CA) | Molecule Info | [1] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | Calcium signaling pathway | |||
| 3 | cGMP-PKG signaling pathway | |||
| 4 | Oocyte meiosis | |||
| 5 | Apoptosis | |||
| 6 | Wnt signaling pathway | |||
| 7 | Axon guidance | |||
| 8 | VEGF signaling pathway | |||
| 9 | Osteoclast differentiation | |||
| 10 | Natural killer cell mediated cytotoxicity | |||
| 11 | T cell receptor signaling pathway | |||
| 12 | B cell receptor signaling pathway | |||
| 13 | Long-term potentiation | |||
| 14 | Glutamatergic synapse | |||
| 15 | Dopaminergic synapse | |||
| 16 | Oxytocin signaling pathway | |||
| 17 | Glucagon signaling pathway | |||
| 18 | Alzheimer's disease | |||
| 19 | Amyotrophic lateral sclerosis (ALS) | |||
| 20 | Amphetamine addiction | |||
| 21 | Tuberculosis | |||
| 22 | HTLV-I infection | |||
| Reactome | DARPP-32 events | Click to Show/Hide | ||
| 2 | FCERI mediated Ca+2 mobilization | |||
| 3 | Ca2+ pathway | |||
| WikiPathways | Mitochondrial Gene Expression | Click to Show/Hide | ||
| 2 | MAPK Signaling Pathway | |||
| 3 | G Protein Signaling Pathways | |||
| 4 | Cardiac Hypertrophic Response | |||
| 5 | Fc epsilon receptor (FCERI) signaling | |||
| 6 | Signaling by the B Cell Receptor (BCR) | |||
| 7 | T-Cell Receptor and Co-stimulatory Signaling | |||
| 8 | Amyotrophic lateral sclerosis (ALS) | |||
| 9 | Spinal Cord Injury | |||
| 10 | Alzheimers Disease | |||
| 11 | miR-targeted genes in muscle cell - TarBase | |||
| 12 | miR-targeted genes in lymphocytes - TarBase | |||
| 13 | Opioid Signalling | |||
| 14 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 15 | Physiological and Pathological Hypertrophy of the Heart | |||
